Bone metabolism: A note on the significance of mouse models

Physiological Research

Volumn 58, Issue 4, 2009, Pages 459-471

  Raska O ^a   Bernaskova K ^a   Raška, Jr ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Bone remodelling; Diabetes; Obesity; Osteoblast; Osteocalcin; Osteoclast; Osteoporosis

Indexed keywords

OSTEOCALCIN;

ANIMAL; ANIMAL MODEL; BIOLOGICAL MODEL; BONE; BONE DISEASE; ENERGY METABOLISM; HUMAN; METABOLISM; MOUSE; OBESITY; OSTEOBLAST; OSTEOPOROSIS; SHORT SURVEY;

ANIMALS; BONE AND BONES; BONE DISEASES; ENERGY METABOLISM; HUMANS; MICE; MODELS, ANIMAL; MODELS, BIOLOGICAL; OBESITY; OSTEOBLASTS; OSTEOCALCIN; OSTEOPOROSIS;

EID: 72549117643     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (92)

1. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M: TSH is a negative regulator of skeletal remodeling. Cell 115: 151-162, 2003.
2. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF: Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 355: 763-778, 2006.
3. Astudillo P, Rios S, Pastenes L, Pino AM, Rodriguez JP: Increased adipogenesis of osteoporotic human-mesenchymal stem cells (MSCs) characterizes by impaired leptin action. J Cell Biochem 103: 1054-1065, 2008.
4. Baldock PA, Allison SJ, Lundberg P, Lee NJ, Slack K, Lin EJ, Enriquez RF, McDonald MM, Zhang L, During MJ, Little DG, Eisman JA, Gardiner EM, Yulyaningsih E, Lin S, Sainsbury A, Herzog H: Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem 282: 19092-19102, 2007.
5. Bassett JH, Nordstrom K, Boyde A, Howell PG, Kelly S, Vennstrom B, Williams GR: Thyroid status during skeletal development determines adult bone structure and mineralization. Mol Endocrinol 21: 1893-1904, 2007a.
6. Bassett JH, O'Shea PJ, Sriskantharajah S, Rabier B, Boyde A, Howell PG, Weiss RE, Roux JP, Malaval L, Clement-Lacroix P, Samarut J, Chassande O, Williams GR: Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. Mol Endocrinol 21: 1095-1107, 2007b.
7. Bassett JH, Williams AJ, Murphy E, boyde A, Howell PG, Swinhoe R, Archanco M, Flamant F, Samarut J, Costagliola S, Vassart G, Weiss RE, Refetoff S, Williams GR: A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism. Mol Endocrinol 22: 501-512, 2008.
8. Berkner KL: The vitamin K-dependent carboxylase. Annu Rev Nutr 25: 127-149, 2005.
9. Bisello A, Horwitz MJ, Stewart AF: Parathyroid hormone-related protein: an essential physiological regulator of adult bone mass. Endocrinology 145: 3551-3553, 2004.
10. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 423: 337-342, 2003.
11. Broadus AE, Mangin M, Ikeda K, Insogna KL, Weir EC, Burtis WJ, Stewart AF: Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide. N Engl J Med 319: 556-563, 1988.
12. Burguera B, Hofbauer LC, Thomas T, Gori F, Evans GL, Khosla S, Riggs BL, Turner RT: Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology 142: 3546-3553, 2001.
13. Canalis E, Giustina A, Bilezikian JP: Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357: 905-916, 2007.
14. Cirmanová V, Bayer M, Stárka L, Zajíčková K: The effect of leptin on bone - an evolving concept of action. Physiol Res 57 (Suppl 1): S143-S151, 2008.
15. Clowes JA, Riggs BL, Khosla S: The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 208: 207-227, 2005.
16. Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, Grey AB, Broom N, Myers DE, Nicholson GC, Reid IR: Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 175: 405-415, 2002.
17. Cousin W, Courseaux A, Ladoux A, Dani C, Peraldi P: Cloning of hOST-PTP: the only example of a protein-tyrosine-phosphatase the function of which has been lost between rodent and human. Biochem Biophys Res Commun 321: 259-265, 2004.
18. Demay MB: Mechanism of vitamin D receptor action. Ann N Y Acad Sci 1068: 204-213, 2006.
19. Dovio A, Perazzolo L, Osella G, Ventura M, Termine A, Milano E, Bertolotto A, Angeli A: Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, shortterm glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 89: 4923-4928, 2004.
20. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G: Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100: 197-207, 2000.
21. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G: Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434: 514-520, 2005.
22. Ferron M, Hinoi E, Karsenty G, Ducy P: Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 105: 5266-5270, 2008.
23. Fu L, Patel MS, Bradley A, Wagner EF, Karsenty G: The molecular clock mediates leptin-regulated bone formation. Cell 122: 803-815, 2005.
24. Gallo J, Raška M, Mrázek F, Petřek M: Bone remodeling, particle disease and individual susceptibility to periprosthetic osteolysis. Physiol Res 57: 339-349, 2008.
25. Gerdhem P, Isaksson A, Akesson K, Obrant KJ: Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int 16: 1506-1512, 2005.
26. Greenspan SL, Resnick NM, Parker RA: Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90: 2762-2767, 2005.
27. Harada S, Rodan GA: Control of osteoblast function and regulation of bone mass. Nature 423: 349-355, 2003.
28. Hase H, Ando T, Eldeiry L, Brebene A, Peng Y, Liu L, Amano H, Davies TF, Sun L, Zaidi M, Abe E: TNFalpha mediates the skeletal effects of thyroid-stimulating hormone. Proc Natl Acad Sci USA 103: 12849-12854, 2006.
29. Hauschka PV, Lian JB, Cole DE, Gundberg CM: Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69: 990-1047, 1989.
30. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL: The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15: 2-12, 2000.
31. Hofbauer LC, Brueck CC, Singh SK, Dobnig H: Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 22: 1317-1328, 2007.
32. Hoff AO, Catala-Lehnen P, Thomas PM, Priemel M, Rueger JM, Nasonkin I, Bradley A, Hughes MR, Ordonez N, Cote GJ, Amling M, Gagel RF: Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest 110: 1849-1857, 2002.
33. Holloway WR, Collier FM, Aitken CJ, Myers DE, Hodge JM, Malakellis M, Gough TJ, Collier GR, Nicholson GC: Leptin inhibits osteoclast generation. J Bone Miner Res 17: 200-209, 2002.
34. Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF: Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88: 569-575, 2003.
35. Inaba M: Secondary osteoporosis: thyrotoxicosis, rheumatoid arthritis, and diabetes mellitus. J Bone Miner Metab 22: 287-292, 2004.
36. Iqbal J, Sun L, Kumar TR, Blair HC, Zaidi M: Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci USA 103: 14925-14930, 2006.
37. Jilka RL: Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40: 1434-1446, 2007.
38. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC: Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104: 439-446,1999.
39. Kameda T, Mano H, Yuasa T, Mori Y, Miyazawa K, Shiokawa M, Nakamaru Y, Hiroi E, Hiura K, Kameda A, Yang NN, Hakeda Y, Kumegawa M: Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med 186: 489-495, 1997.
40. Karsenty G: Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab 4: 341-348, 2006.
41. Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, Frenette PS: Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 124: 407-421, 2006.
42. Kawano H, Sato T, Yamada T, Matsumoto T, Sekine K, Watanabe T, Nakamura T, Fukuda T, Yoshimura K, Yoshizawa T, Aihara K, Yamamoto Y, Nakamichi Y, Metzger D, Chambon P, Nakamura K, Kawaguchi H, Kato S: Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci USA 100: 9416-9421, 2003.
43. Khosla S: Minireview: the OPG/RANKL/RANK system. Endocrinology 142: 5050-5055, 2001.
44. Khosla S: Leptin-central or peripheral to the regulation of bone metabolism? Endocrinology 143: 4161-4164, 2002.
45. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teitelbaum SL: Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116: 2152-2160, 2006.
46. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC: Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298: 843-846, 2002.
47. Křížová J, Dolínková M, Lacinová Z, Sulek S, Doležalová R, Housová J, Krajíčková J, Haluzíková D, Bošanská L, Papežová H, Haluzík M: Adiponectin and resistin gene polymorphisms in patients with anorexia nervosa and obesity and its influence on metabolic phenotype. Physiol Res 57: 539-546, 2008.
48. Kronenberg HM: PTHrP and skeletal development. Ann N Y Acad Sci 1068: 1-13, 2006.
49. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M: Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 27: 535-545, 2008.
50. Kushner JA, Ciemerych MA, Sicinska E, Wartschow LM, Teta M, Long SY, Sicinski P, White MF: Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth. Mol Cell Biol 25: 3752-3762, 2005.
51. Laharrague P, Larrouy D, Fontanilles AM, Truel N, Campfield A, Tenenbaum R, Galitzky J, Corberand JX, Penicaud L, Casteilla L: High expression of leptin by human bone marrow adipocytes in primary culture. FASEB J 12: 747-752, 1998.
52. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, Mckee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G: Endocrine regulation of energy metabolism by the skeleton. Cell 130: 456-469, 2007.
53. Liedert A, Kaspar D, Blakytny R, Claes L, Ignatius A: Signal transduction pathways involved in mechanotransduction in bone cells. Biochem Biophys Res Commun 349: 1-5, 2006.
54. Liu YJ, Shen H, Xiao P, Xiong DH, Li LH, Recker RR, Deng HW: Molecular genetic studies of gene identification for osteoporosis: a 2004 update. J Bone Miner Res 21: 1511-1535, 2006.
55. Lundberg P, Allison SJ, Lee NJ, Baldock PA, Brouard N, Rost S, Enriquez RF, Sainsbury A, Lamghari M, Simmons P, Eisman JA, Gardiner EM, Herzog H: Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J Biol Chem 282: 19082-19091,2007.
56. Manolagas SC, Kousteni S, Jilka RL: Sex steroids and bone. Recent Prog Horm Res 57: 385-409, 2002.
57. Martin TJ, Quinn JM, Gillespie MT, Ng KW, Karsdal MA, Sims NA: Mechanisms involved in skeletal anabolic therapies. Ann N Y Acad Sci 1068: 458-470, 2006.
58. Miao D, He B, Jiang Y, Kobayashi T, Soroceanu MA, Zhao J, Su H, Tong X, Amizuka N, Gupta A, Genant HK, Kronenberg HM, Goltzman D, Karaplis AC: Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest 115: 2402-2411, 2005.
59. Morrison DF, Mauro LJ: Structural characterization and chromosomal localization of the mouse cDNA and gene encoding the bone tyrosine phosphatase, mOST-PTP. Gene 257: 195-208, 2000.
60. Mundy GR, Guise TA: Hormonal control of calcium homeostasis. Clin Chem 45: 1347-1352, 1999.
61. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S: Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130: 811-823, 2007.
62. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434-1441, 2001.
63. Otabe S, Yuan X, Fukutani T, Wada N, Hashinaga T, Nakayama H, Hirota N, Kojima M, Yamada K: Overexpression of human adiponectin in transgenic mice results in suppression of fat accumulation and prevention of premature death by high-calorie diet. Am J Physiol 293: E210-E218, 2007.
64. Patel MS, Elefteriou F: The new field of neuroskeletal biology. Calcif Tissue Int 80: 337-347, 2007.
65. Price PA: Gla-containing proteins of bone. Connect Tissue Res 21: 51-57; discussion 57-60, 1989.
66. Raška I, JR., Broulík P: The impact of diabetes mellitus on skeletal health: an established phenomenon with inestablished causes? Prague Med Rep 106: 137-148, 2005.
67. Rosato MT, Schneider SH, Shapses SA: Bone turnover and insulin-like growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus. Calcif Tissue Int 63: 107-111, 1998.
68. Sato S, Hanada R, Kimura A, Abe T, Matsumoto T, Iwasaki M, Inose H, Ida T, Mieda M, Takeuchi Y, Fukumoto S, Fujita T, Kato S, Kangawa K, Kojima M, Shinomiya K, Takeda S: Central control of bone remodeling by neuromedin U. Nat Med 13: 1234-1240, 2007.
69. Sato T, Kawano H, Kato S: Study of androgen action in bone by analysis of androgen-receptor deficient mice. J Bone Miner Metab 20: 326-330, 2002.
70. Semenkovich CF: Insulin resistance and atherosclerosis. J Clin Invest 116: 1813-1822, 2006.
71. Semenkovich CF, Teitelbaum SL: Bone weighs in on obesity. Cell 130: 409-411, 2007.
72. Schiller KR, Mauro LJ: Tyrosine phosphatases as regulators of skeletal development and metabolism. J Cell Biochem 96: 262-277, 2005.
73. Schwartz AV, Sellmeyer DE: Diabetes, fracture, and bone fragility. Curr Osteoporos Rep 5: 105-111, 2007.
74. Singh MK, Elefteriou F, Karsenty G: Cocaine and amphetamine-regulated transcript may regulate bone remodeling as a circulating molecule. Endocrinology 149: 3933-3941, 2008.
75. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R: Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem 276: 8836-8840, 2001.
76. Štěpán JJ, Alenfeld F, Boivin G, Feyen JH, Lakatos P: Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 37: 225-238, 2003.
77. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, Zaidi S, Zhu LL, Yaroslavskiy BB, Zhou H, Zallone A, Sairam MR, Kumar TR, Bo W, Braun J, Cardoso-Landa L, Schaffler MB, Moonga BS, Blair HC, Zaidi M: FSH directly regulates bone mass. Cell 125: 247-260, 2006.
78. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G: Leptin regulates bone formation via the sympathetic nervous system. Cell 111: 305-317, 2002.
79. Teitelbaum SL: Osteoclasts: what do they do and how do they do it? Am J Pathol 170: 427-435, 2007
80. Teitelbaum SL, Ross FP: Genetic regulation of osteoclast development and function. Nat Rev Genet 4: 638-649, 2003.
81. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL: Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140: 1630-1638, 1999.
82. Tremollieres FA, Pouilles JM, Ribot C: Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab 77: 683-686, 1993.
83. Weinstein RS: Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2: 65-73, 2001.
84. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102: 274-282, 1998.
85. Woodrow JP, Sharpe CJ, Fudge NJ, Hoff AO, Gagel RF, Kovacs CS: Calcitonin plays a critical role in regulating skeletal mineral metabolism during lactation. Endocrinology 147: 4010-4021, 2006.
86. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, Leroith D: Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 110: 771-781, 2002.
87. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941-946, 2001.
88. Zaidi M: Skeletal remodeling in health and disease. Nat Med 13: 791-801, 2007.
89. Zhang F, Chen Y, Heiman M, Dimarchi R: Leptin: structure, function and biology. Vitam Horm 71: 345-372, 2005.
90. Zhang M, Xuan S, Bouxsein ML, Von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL: Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 277: 44005-44012, 2002.
91. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432, 1994.
92. Zikán V, Štěpán JJ: Plasma type 1 collagen cross-linked C-telopeptide: a sensitive marker of acute effects of salmon calcitonin on bone resorption. Clin Chim Acta 316: 63-69, 2002.